New approval: IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

IMFINZI + EP EXTENDED SURVIVAL
IN FIRST-LINE ES-SCLC1

SUPERIOR OVERALL SURVIVAL AT INTERIM ANALYSIS1*
-MONTH mOS WITH IMFINZI + EP
VS (P=0.0047)
-MONTH mOS WITH EP ALONE
UPDATED ANALYSIS OVERALL SURVIVAL2†
Median duration of follow-up 25.1 months

ES-SCLC=extensive-stage small cell lung cancer; EP=etoposide and either carboplatin or cisplatin; mOS=median overall survival; PFS=progression-free survival; CI=confidence interval; HR=hazard ratio.

*Overall survival was the primary endpoint. At the time of the planned interim overall survival analysis with a median duration of follow-up of 14.2 months, mOS was 13 months (95% CI, 11.5-14.8) with IMFINZI + EP vs 10.3 months (95% CI, 9.3-11.2) with EP alone (HR=0.73; 95% CI, 0.59-0.91; P=0.0047).1,3

At time of updated analysis, mOS was 12.9 months (95% CI, 11.3-14.7) with IMFINZI + EP vs 10.5 months (95% CI, 9.3-11.2) with EP alone (HR=0.75; 95% CI, 0.62-0.91).2

References: 1.IMFINZI, Summary of Product Characteristics. September 2020 2. Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC: updated results from the phase III CASPIAN study. J Clin Oncol. 2020;38(15 suppl). Published online May 25, 2020. doi:10.1200/JCO.2020.38.15_suppl.9002. 3. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939.

IMPORTANT SAFETY INFORMATION